Tuesday, January 18, 2011
Advaxis Inc., of North Brunswick, N.J., received approval from the data safety monitoring board to dose remaining patients in its trial of ADXS11-001 immunotherapy in cervical dysplasia.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.